Episode Details
Back to EpisodesDiffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations
Season 10
Published 6 months, 4 weeks ago
Description
In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.
Featured Articles:
- Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment
- Plasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolism
- Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer